Systematic reviews & meta-analyses


Rosenthal A, Conde G, Greco JF, Gharavi NM. Management of androgenic alopecia: a systematic review of the literature. J Cosmet Laser Ther. 2024. doi:10.1080/14764172.2024.2362126 • PubMed

Uleri A, Nicolas Cornu J, Gobbo A, et al. Association of 5α-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis. Eur Urol Focus. 2024. doi:10.1016/j.euf.2024.04.009 • PubMed

Wang Y, Song Y, Peng Y, et al. Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: an updated systematic review and meta-analysis. Urol Oncol. 2024. doi:10.1016/j.urolonc.2024.04.014 • PubMed


Baboudjian M, Gondran-Tellier B, Dariane C, et al. Association between 5α-reductase inhibitors and prostate cancer mortality: a systematic review and meta-analysis. JAMA Oncol. 2023. doi:10.1001/jamaoncol.2023.0260 • PubMed • PMCID: PMC10119773 (full text available 4/20/2024)

Nobari NN, Roohaninasab M, Sadeghzadeh-Bazargan A, et al. A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia. Adv Clin Exp Med. 2023. DOI • PubMed

Santana FFV, Lozi AA, Gonçalves RV, Da Silva J, Da Matta SLP. Comparative effects of finasteride and minoxidil on the male reproductive organs: a systematic review of in vitro and in vivo evidence. Toxicol Appl Pharmacol. 2023. doi:10.1016/j.taap.2023.116710 • PubMed


Christou CD, Esagian SM, Ziakas N, Prousali E, Tzamalis A. Factors predisposing to intraoperative floppy iris syndrome (IFIS): an updated systematic review and meta-analysis. J Cataract Refract Surg. 2022 Jul 20. DOIPubMed

Hui EX, Huang X, Oon HH. Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity. Andrology. 2022 Oct. DOI • PubMed [Not a systematic review, but included here because of its broad scope, covering 131 medications with evidence from 67 studies.]

Li Y, Ma J, Qin XH, Hu CY. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Transl Androl Urol. 2022. DOI • PubMed • PMC full text

Zhang JJ, Shi X, Wu T, et al. Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis. Asian J Androl. 2022. DOI • PubMed


Baldessarini RJ, Pompili M. Further studies of effects of finasteride on mood and suicidal risk. J Clin Psychopharmacol. 2021 Nov-Dec 01. DOIPubMed

Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ. Risk of depression associated with finasteride treatment. J Clin Psychopharmacol. 2021 Mar 31. DOI • PubMed


Busetto GM, Del Giudice F, D’Agostino D, et al. Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: a critical review of the literature. Arch Ital Urol Androl. 2020. DOI • PubMed

Chen L, Zhang J, Wang L, Wang H, Chen B. The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: a systematic review and meta-analysis. Aesthetic Plast Surg. 2020 Jun. DOI • PubMed

Deng T, Duan X, He Z, Zhao Z, Zeng G. Association between 5-alpha reductase inhibitor use and the risk of depression: a meta-analysis. Urol J. 2020. DOI • PubMed

Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020 Nov. DOI • PubMed

Kim JH, Shim SR, Khandwala Y, Del Giudice F, Sorensen S, Chung BI. Risk of depression after 5 alpha reductase inhibitor medication: meta-analysis. World J Mens Health. 2020 Oct. DOI • PubMed

Wang L, Lei Y, Gao Y, et al. Association of finasteride with prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Apr. DOI • PubMedPMC full text

Zhou Z, Cui Y, Wu J, Jin H. Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Exp Ther Med. 2020. DOI • PubMed


Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol. 2019. DOI • PubMed

Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-reductase inhibitors raise circulating serum testosterone levels? A comprehensive review and meta-analysis to explaining paradoxical results. Sex Med Rev. 2019. DOI • PubMed

Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS. Sexual dysfunction in men taking systemic dermatologic medication: a systematic review. J Am Acad Dermatol. 2019. DOI • PubMed

Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: a systematic review. J Am Acad Dermatol. 2019 Apr. DOIPubMed

Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019 Mar 11. DOIPubMedPMC full text

Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019. DOI • PubMed

See also: Research briefing on two systematic reviews/meta-analyses published in 2019.


Kim JH, Baek MJ, Sun HY, et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: a meta-analysis. PLoS One. 2018. DOI • PubMed

Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018. Journal site • PubMed


Corona G, Tirabassi G, Santi D, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017. DOI • PubMed


Belknap SM, Aslam I, Kiguradze T, et al. Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis. JAMA Dermatol. 2015. DOI • PubMed

Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016. DOIPubMed

Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016. PubMed

Liu L, Zhao S, Li F, et al. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016. DOIPubMed


Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014 Jun. DOIPubMed

Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014. DOIPubMed


Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010. DOIPubMed

Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010. DOIPubMed • PMC full text